Immunohistochemical localization of RANK, RANKL and OPG in healthy and arthritic canine elbow joints

Veterinary Surgery

Volumn 38, Issue 6, 2009, Pages 780-786

  Spahni, Andrea I ^a,b   Schawalder, Peter ^a,b   Rothen, Barbara ^a,b   Bosshardt, Dieter D ^a,b   Lang, Niklaus ^a,b   Stoffel, Michael H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE; BONE REMODELING; CYTOLOGY; DOG; DOG DISEASE; FLUORESCENCE MICROSCOPY; FORELIMB; GENETICS; METABOLISM; OSTEOARTHRITIS; PHYSIOLOGY;

ANIMALS; BONE AND BONES; BONE REMODELING; DOG DISEASES; DOGS; FORELIMB; MICROSCOPY, FLUORESCENCE; OSTEOARTHRITIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

CANIS FAMILIARIS;

EID: 68749105048     PISSN: 01613499     EISSN: 1532950X     Source Type: Journal    
DOI: 10.1111/j.1532-950X.2009.00566.x     Document Type: Article

References (28)

1. Vaes G : Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation, and mode of action of osteoclasts. Clin Orthop Relat Res 231 : 239 271, 1988
2. Miyamoto T, Suda T : Differentiation and function of osteoclasts. Keio J Med 52 : 1 7, 2003
3. Rehman Q, Lane NE : Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis. Arthritis Res 3 : 221 227, 2001
4. Lajeunesse D, Martel-Pelletier J, Fernandes JC, et al : Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis. Ann Rheum Dis 63 : 78 83, 2004
5. Spähnhauer Z Aetiopathogenetische Untersuchung der gestörten Knochentrophik als Ursache von artikulären Entwicklungsstörungen, Gelenksdegeneration/-destruktion und Überprüfung eines neuen Therapieansatzes [Etiopathogenetic investigations of trophic disorders in bone relating to developmental malformation of joints, to degenerative joint diseases and to joint distruction and assessment of new therapeutic approaches]. Doctoral Thesis, Bern, 2004.
6. Schawalder P, Stich H, Spähnhauer Z, et al : Der lahmende Junghund [Lameness in young dogs]. Der Veterinärspiegel 1 : 6 12, 2006
7. Schawalder P, Stich H, Steidel T, et al : Die " Ellbogendysplasie" beim Hund. - Eine klinisch synoptische Betrachtungsweise der verschiedenen Erscheinungsbilder mit ätiopathologischen Überlegungen, Teil 1 [Elbow dysplasia in dogs A clinical synopsis of the different manifestations and etiopathogenetic considerations, part 1]. Der Veterinärspiegel 4 : 237 240, 2001
8. Schawalder P, Stich H, Steidel T, et al : Die " Ellbogendysplasie" beim Hund. - Eine klinisch synoptische Betrachtungsweise der verschiedenen Erscheinungsbilder mit ätiopathologischen Überlegungen, Teil 2 [Elbow dysplasia in dogs A clinical synopsis of the different manifestations and etiopathogenetic considerations, part 2]. Der Veterinärspiegel 1 : 14 27, 2002
9. Hsu H, Lacey DL, Dunstan CR, et al : Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 : 3540 3545, 1999
10. Hofbauer LC, Heufelder AE : Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79 : 243 253, 2001
11. Lossdorfer S, Gotz W, Jager A : Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. Calcif Tissue Int 71 : 45 52, 2002
12. Boyle WJ, Simonet WS, Lacey DL : Osteoclast differentiation and activation. Nature 423 : 337 342, 2003
13. Yasuda H, Shima N, Nakagawa N, et al : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 : 3597 3602, 1998
14. Choi Y, Woo KM, Ko SH, et al : Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 31 : 2179 2188, 2001
15. Kong YY, Feige U, Sarosi I, et al : Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 : 304 309, 1999
16. Shiotani A, Takami M, Itoh K, et al : Regulation of osteoclast differentiation and function by receptor activator of NFκB ligand and osteoprotegerin. Anat Rec 268 : 137 146, 2002
17. Walsh MC, Choi Y : Biology of the TRANCE axis. Cytokine Growth Factor Rev 14 : 251 263, 2003
18. Gravallese EM : Bone destruction in arthritis. Ann Rheum Dis 61 (Suppl 2) : ii84 ii86, 2002
19. Boyce BF, Xing L : Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 9 (Suppl 1) : S1, 2007
20. Wang R, Zhang L, Zhang X, et al : Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells. Eur J Immunol 32 : 1090 1098, 2002
21. Arron JR, Choi Y : Bone versus immune system. Nature 408 : 535 536, 2000
22. Pettit AR, Ji H, von Stechow D, et al : TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159 : 1689 1699, 2001
23. Min H, Morony S, Sarosi I, et al : Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192 : 463 474, 2000
24. Suda T, Takahashi N, Udagawa N, et al : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20 : 345 357, 1999 (Pubitemid 30649812)
25. Atkins GJ, Bouralexis S, Haynes DR, et al : Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28 : 370 377, 2001
26. Kirberger RM, Fourie SL : Elbow dysplasia in the dog: pathophysiology, diagnosis and control. J S Afr Vet Assoc 69 : 43 54, 1998
27. Brandstrom H, Bjorkman T, Ljunggren O : Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 280 : 831 835, 2001
28. McClung MR : Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 4 : 28 33, 2006